Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Eprodisate disodium (Kiacta) for AA amyloidosis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives AA amyloidosis is a rare and serious condition that can happen as a complication of other chronic diseases such as rheumatoid arthritis. It leads to abnormal proteins being deposited throughout the body, but particularly affects the kidneys. Many patients eventually have kidney failure and need to start dialysis. At the moment, there is no treatment for AA amyloidosis itself, only the chronic disease that is causing it.
Eprodisate disodium (Kiacta) is a new drug being developed for AA amyloidosis. It is taken as a tablet twice a day. A study is currently running to see how well it works and whether it is safe to use.
If it is licensed in the UK, eprodisate disodium will be the first treatment specifically available for people with AA amyloidosis. Indexing Status Subject indexing assigned by CRD MeSH Amyloidosis; Humans; Propane; Sulfonic Acids Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000413 Date abstract record published 04/03/2016 |